COR vs HSIC
COR: Cencora is a critical link in the global healthcare supply chain, providing pharmaceutical distribution, commercialization services, and specialty drug support to ensure patients have access to life-saving medications. HSIC: Henry Schein is a leading global distributor of dental and medical supplies, equipment, and practice management software for office-based healthcare practitioners.
Side-by-side fundamentals
| Metric | COR | HSIC | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $321.35 | $84.63 | |
| Market cap | $61.3B | $9.4B | |
| P/E as of 2026-10-08 | 23.89 | 24.66 | COR lower |
| Net margin FY2025, SEC XBRL | +0.5% | +3.0% | HSIC higher |
| Gross margin FY2025, SEC XBRL | +3.6% | +31.1% | HSIC higher |
| Operating margin FY2025, SEC XBRL | +0.8% | +5.0% | HSIC higher |
| ROE FY2025, SEC XBRL | +103.1% | +10.2% | COR higher |
| ROA FY2025, SEC XBRL | +2.0% | +3.5% | HSIC higher |
| Debt / equity as of 2026-09-03 | 3.84 | 1.10 | HSIC lower |
| Revenue growth (YoY) as of 2026-09-03 | +5.1% | +6.5% | HSIC higher |
| Revenue CAGR (3y) SEC XBRL | +10.4% | +1.4% | COR higher |
| Dividend yield as of 2026-09-03 | +0.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | 0 | COR higher |
| Beta as of 2026-09-03 | -0.03 | 0.56 | |
| 1-year return as of 2026-10-08 close | +3.5% | +30.7% | HSIC higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.